Search Results

1 - 10 of 93 items :

  • "prostate cancer" x
  • Clinical Medicine, other x
Clear All
Metastatic Prostate Cancer with Highest Reported PSA Level

References 1. Grönberg H. Prostate cancer epidemiology. Lancet Lond Engl. 2003;361(9360):859–864. 2. Globocan 2012. Available from: http://globocan.iarc.fr/Default.aspx 3. Benoit RM, Naslund MJ. The socioeconomic implications of prostate-specific antigen screening. Urol Clin North Am. 1997;24(2):451–458. 4. Krpina K, Markić D, Rahelić D, Ahel J, Rubinić N, Španjol J. 10-year survival of a patient with metastatic prostate cancer: Case report and literature review. Arch Ital Urol Androl. 2015;87(3):252-3. doi: 10.4081/aiua.2015

Open access
Prostate cancer: an occupational hazard in Romania?

References 1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer. 2018;103:356–87. 2. Taitt H.E. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. Am J Mens Health.2018;12:1807–23. 3. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International

Open access
Obesity is Associated with Upgrading in Prostate Cancers

REFERENCES 1. Allott EH, Masko EM, Freedland SJ. Obesity and Prostate Cancer: Weighing the Evidence. European Urology 2013;63:800-9. 2. Altay B, Erkurt B, Guzelburc V, et al. Impact of obesity on functional and oncological outcomes in radical perineal prostatectomy. CUAJ 2015;9:766-9. 3. Gbenou MCG, Peltier A, Schulman CC, et al. Increased body mass index as a risk factor in localized prostate cancer treated by radical prostatectomy. Urol Oncol 2016;34(6):254.e1-6. 4. Jayachandran J, Aronson WJ, Terris MK, et al. Obesity and positive

Open access
Repeat transrectal prostate biopsies in diagnosing prostate cancer

References 1. Yanke BV, Gonen M, Scardino PT, Kattan MW. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol 2005;173:421-4. 2. Smilov N, Mladenov D. Repeated prostate biopsy in patients with continuous suspicion for present prostate carcinoma. Urology 2011;17:6-13. 3. Rodriguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 1998;160:2115-20. 4

Open access
Contemporary Distribution of High-Grade Prostate Cancer in the Circumstances of Opportunistic Testing

References 1. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. (2015). Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 51(9):1164-87. doi: 10.1016/j. ejca.2013.09.002. 2. Hoffman RM, Meisner AL, Arap W, Barry M, Shah SK, Zeliadt SB, et al. (2016). Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995-2012. Cancer Epidemiol Biomarkers Prev. 25(2):259-63. doi: 10.1158/1055-9965.EPI

Open access
Dosimetric Comparison: Intensity Modulated Radiation Therapy Vs. 3D Conformal Radiotherapy In Prostate Cancer Radical Treatment

REFERENCES 1. Jemal A, Center MM, De Santis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarker Prev 2010; 19(8):1893-907. 2. NCCN Guidelines Version 1.2018. Prostate cancer. January 2018. 3. Brundage M, Lukka H, Crook J, et al. The use of conformal radiotherapy ant the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer-a systematic review. Radiother Oncol 2002; 64(3):12. 4. Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity

Open access
Mir-15A Reconstitution in Prostate Cancer Cell Line Suppresses Cancer Progression Through Down Regulation of MYB and Androgen Receptor Upregulation

, 2005 102(39), 13944-9. 4. Heinlein C. A. et C. Chang. Androgen receptor in prostate cancer. - Endocr. Rev., 25, 2004, N 2, 276-308. 5. Jun-jie YU and XIA Shu-jie. Novel role of microRNAs in prostate cancer. - Chin. Med. J., 126, 2013; N15, 2960-4. 6. Kalkbrenner F., S. Guehmann et K. Moelling. Transcriptional activation by human c-myb and v-myb genes. - Oncogene, 5, 1990, N 5, 657-661. 7. Lagos-Quintana M., R. Rauhut, A. Yalcin et al. Identification of tissue-specific MicroRNAs from mouse. - Curr. Biol

Open access
Lack of ERG-antibody in Benign Mimickers of Prostate Cancer

, Epstein JI. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol 2005;29:874-80. 4. Brimo F, Epstein JI. Immunohistochemical pitfalls in prostate pathology. Human Pathology 2012;43:313‑24 5. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648. 6. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2:ERG fusion

Open access
Role of transurethral resection of the prostate in the management of prostate cancer

References: 1. Dae Keun Kim, Sang Jin Kim, Hong Sang Moon, et al. The role of TURP in the detection of prostate cancer in BPH patients with previously negative prostate biopsy. www.kjurology.org DOI:10.4111/kju.2010.51.5.313. 2. S Radhakrishnan, TJ Dorkin, N Sheikh & DR Greene. Role of transition zone sampling by TURP in patients with raised PSA and multiple negative transrectal ultrasound-guided prostatic biopsies. Prostate Cancer and Prostatic Diseases 2004:7;338–342. 3. Koenraad van Renterghem, Gommert Van Koeveringe, Ruth Achten, Philip

Open access
Role of Vitamin D as an Anti-Proliferative Compound on Prostate Cancer

References 1. Nystrand A. Cancer i siffror. EPC, Cancer fonden. ISBN 9189446682; 2003. 2. Tamaro SH, Diane KH, Stephen DH, Nomeli PN, Thomas TYW, Heather AY, Praveen A, Jeffrey EG, et al. Inhibition of Prostate Cancer Growth by Muscadine Grape Skin Extract and Resveratrol through Distinct Mechanisms. Cancer Res 2007; 67: 17. http://dx.doi.org/10.1158/0008-5472.CAN-06-4069 3. Zhao XY, Feldman D. The role of vitamin D in prostate cancer. Steroids 2001; 66: 293-300. http://dx.doi.org/10.1016/S0039-128X(00

Open access